Latest News
- November 18, 2025ANDA application for Bimatoprost ophthalmic solution received Marketing Authorization from the USFDA!
- November 12, 2025ANDA application for Risperidone extended-release injectable suspension has received Marketing Authorization from the USFDA!
- October 30, 2025Accelerating Clinical Research!
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
- August 08, 2025International Publication of Phase II clinical Trial
Webinar: Overview of the 505(b)(2) regulatory pathway for NDA
Keen on learning best practices, seize opportunities, and overcome challenges linked to IND submissions for products which fall under the 505(b)(2) regulatory pathway?
Access to the latest webinar on:
Overview of the 505(b)(2) regulatory pathway for NDA
Webinar Link: https://www.youtube.com/watch?v=dXW5UA9TFKA
Speakers:
Dr. Sandeep Singh (VP – Clinical Operations & Regulatory Affairs, CBCC Global Research)
Ankit Parikh (Senior Manager – Medical Writing & Regulatory Affairs, CBCC Global Research)
Moderator:
Manoj Bharathi (Director – Corporate Development, CBCC Global Research)
In this webinar, our expert will cover the unique components and customizations involved in 505(b)(2) IND submissions and study requirements.
You will learn:
Underlying common bottlenecks, regulatory requirements, as well as mitigating risk while charting out plans to stay ahead of timelines.
